Power3, New Horizons to Co-develop Tests for Neurodegenerative Disease | GenomeWeb

NEW YORK, March 28 (GenomeWeb News) - Proteomics company Power3 Medical Products and New Horizons Diagnostics plan to use Power3's protein biomarkers to co-develop antibody-based diagnostics for neurodegenerative diseases, the firms said today.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.